

Date of preparation: 30 March 2026

Issuer's abbreviated name: SYNEKTIK SA

Current report: 23/2026 ESPI

Subject: Approval by the Registry Court of the Issuer's division

Legal basis: Article 17 section 1 MAR – confidential information

Body of the report:

Time of publication: 8:34 a.m.

The Management Board of Synektik SA with its registered office in Warsaw ("Issuer") hereby informs that on 27 March 2026 the District Court for the Capital City of Warsaw in Warsaw, XIII Commercial Division of the National Court Register, has registered the division of the Issuer and the registration of Syn2bio SA. Articles of Association concerning an increase in the Syn2bio S.A. share capital in connection with the division of Issuer, as announced by the Issuer in current reports No. 23/2025 of 27 March 2025, No. 37/2025 of 23 July 2025, No. 44/2025 of 3 September 2025, No. 12/2026 of 3 February 2026 and No. 14/2026 of 18 February 2026.

As a result of the Issuer's division into Syn2bio SA, part of the Issuer's assets, comprising a set of tangible and intangible assets, including liabilities, intended for the performance of specific business tasks relating to Kardioznacznik and Centrum Badań and Nowymi Cząsteczkami (Center for Research into New Molecules), which constitute an organized part of the enterprise (division by spin-off), has been transferred. The remaining business activities will continue to be conducted by the Issuer in the same manner.

Following the registration of the Issuer's division, each shareholder is entitled to one share in Syn2bio SA for every share held in the Issuer. In accordance with the division timetable set out in the Syn2bio SA prospectus drawn up in connection with the Issuer's division, 1 April 2026 will be the last trading day on which trading will take place in Synektik SA shares incorporating the right to acquire Syn2bio SA shares.

Persons representing the Issuer:



Cezary Kozanecki – President of the
Management Board